Heart failure & cardiomyopathies

Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial

Eur Heart JPublished Secondary analysis of the ARIES-HM3 randomised trial

Authors' conclusion

The quality of VKA management as measured by TTR correlates with the occurrence of non-surgical bleeding in patients with the HM3 LVAD, with a lower TTR associated with an increased bleeding risk.

Study context

Population
Patients with de-novo HeartMate 3 LVAD on vitamin K antagonists (VKA), randomised to aspirin (100 mg/day) or placebo
Participants
554 patients
Comparison
High time in therapeutic range (TTR) vs low TTR in patients with HM3 LVAD
Primary endpoint
Primary endpoint success, stratified by TTR group
Methodological detailspre-specified analysis, international, double-blind, placebo-controlled
  • Pre-specified analysis
  • International
  • Double-blind
  • Placebo-controlled

Primary result

As reported in the abstract

Primary endpoint success

P = 0.01

Secondary outcomes

Predictors of low TTR

OR (95% CI)
Female sex1.70 (1.12–2.57)
Black race1.62 (1.11–2.35)

TTR interaction with assigned treatment (aspirin vs placebo)

No interaction between assigned treatment group and TTR

Safety

Bleeding, by TTR (higher vs lower) · 12 months

Higher TTR vs lower TTR: bleeding rate
26.4 vs 49.2 events per 100 participant-years
Bleeding rate ratio
1.84 (1.37-2.53) (95% CI)
  • No interaction between assigned treatment and TTR

Stroke, by TTR (higher vs lower)

Higher TTR vs lower TTR: stroke rate
3.2 vs 2.8 events per 100 participant-years
Stroke rate ratio
0.88 (0.30-2.53) (95% CI)
  • No stroke increase with higher TTR

Original publication

Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. Eur Heart J. Published 7 November 2025. doi:10.1093/eurheartj/ehaf745

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.